Magnitude of benefit of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for malignant tumor : A meta-analysis
Copyright © 2020 Elsevier B.V. All rights reserved..
BACKGROUND: The purpose of this study was to analyze the efficacy of PARP inhibitor on solid tumors.
METHODS: For this study, the following databases were searched for articles published from its inception until July 2019: PubMed, Web of Science, EBSCO, and Cochrane library, of which the main conclusion was the overall survival (OS) and progression-free survival (PFS).
RESULTS: We conducted a meta-analysis and the results showed that PARP inhibitor increased the patients' PFS (HR: 0.51, p < 0.001), PFS with BRCA1/2 mutations (HR: 0.32, p < 0.001), OS (HR: 0.74, p < 0.001), OS with BRCA1/2 mutations (HR: 0.78, p = 0.03), complete response (CR) (RR: 1.89, p = 0.10), partial response (PR) (RR: 1.34, p = 0.01), overall response rate (ORR) (RR: 1.42, p = 0.001) respectively. The main adverse events (AEs) observed were decreased appetite.
CONCLUSIONS: PARP inhibitors may prolong survival. PARP inhibitors were more favorable for BRCA1/2 mutations in ovarian cancer patients. Additionally, the overall safety factor was controllable.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:147 |
|---|---|
| Enthalten in: |
Critical reviews in oncology/hematology - 147(2020) vom: 06. März, Seite 102888 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gu, Lihu [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 24.03.2020 Date Revised 24.03.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.critrevonc.2020.102888 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM306135450 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM306135450 | ||
| 003 | DE-627 | ||
| 005 | 20231225122710.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.critrevonc.2020.102888 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1020.xml |
| 035 | |a (DE-627)NLM306135450 | ||
| 035 | |a (NLM)32018126 | ||
| 035 | |a (PII)S1040-8428(20)30026-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gu, Lihu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Magnitude of benefit of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for malignant tumor |b A meta-analysis |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.03.2020 | ||
| 500 | |a Date Revised 24.03.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND: The purpose of this study was to analyze the efficacy of PARP inhibitor on solid tumors | ||
| 520 | |a METHODS: For this study, the following databases were searched for articles published from its inception until July 2019: PubMed, Web of Science, EBSCO, and Cochrane library, of which the main conclusion was the overall survival (OS) and progression-free survival (PFS) | ||
| 520 | |a RESULTS: We conducted a meta-analysis and the results showed that PARP inhibitor increased the patients' PFS (HR: 0.51, p < 0.001), PFS with BRCA1/2 mutations (HR: 0.32, p < 0.001), OS (HR: 0.74, p < 0.001), OS with BRCA1/2 mutations (HR: 0.78, p = 0.03), complete response (CR) (RR: 1.89, p = 0.10), partial response (PR) (RR: 1.34, p = 0.01), overall response rate (ORR) (RR: 1.42, p = 0.001) respectively. The main adverse events (AEs) observed were decreased appetite | ||
| 520 | |a CONCLUSIONS: PARP inhibitors may prolong survival. PARP inhibitors were more favorable for BRCA1/2 mutations in ovarian cancer patients. Additionally, the overall safety factor was controllable | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Adverse events | |
| 650 | 4 | |a BRCA1/2 | |
| 650 | 4 | |a Evaluation of solid tumors | |
| 650 | 4 | |a PARP inhibitor | |
| 650 | 4 | |a Survival | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a BRCA1 Protein |2 NLM | |
| 650 | 7 | |a BRCA2 Protein |2 NLM | |
| 650 | 7 | |a Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a Poly(ADP-ribose) Polymerase Inhibitors |2 NLM | |
| 650 | 7 | |a Adenosine Diphosphate Ribose |2 NLM | |
| 650 | 7 | |a 20762-30-5 |2 NLM | |
| 650 | 7 | |a Poly(ADP-ribose) Polymerases |2 NLM | |
| 650 | 7 | |a EC 2.4.2.30 |2 NLM | |
| 700 | 1 | |a Du, Nannan |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Qiong |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Shengnan |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Laidi |e verfasserin |4 aut | |
| 700 | 1 | |a Mo, Jiahang |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Zefeng |e verfasserin |4 aut | |
| 700 | 1 | |a Mao, Danyi |e verfasserin |4 aut | |
| 700 | 1 | |a Ji, Jia |e verfasserin |4 aut | |
| 700 | 1 | |a Khadaroo, Parikshit Asutosh |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Bangsheng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Critical reviews in oncology/hematology |d 1996 |g 147(2020) vom: 06. März, Seite 102888 |w (DE-627)NLM012606006 |x 1879-0461 |7 nnns |
| 773 | 1 | 8 | |g volume:147 |g year:2020 |g day:06 |g month:03 |g pages:102888 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.critrevonc.2020.102888 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 147 |j 2020 |b 06 |c 03 |h 102888 | ||